Skip to main content
OpenTrials
Completed

NCT Number: NCT04832399

Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Amadora, Portugal

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Documented diagnosis of Relapsing Remitting Multiple Sclerosis (McDonald 2010 Criteria).
  • EDSS ≤ 3.0.
  • Must fulfill Tysabri indication (relapse and MRI criteria).
  • Decision to start treatment with Natalizumab must precede enrollment.
  • Up to four natalizumab infusions.

Key Exclusion Criteria:

  • Any prior treatment with Natalizumab.
  • Prior imunossupressive treatment (Mitoxantrone, Azathioprine, Methotrexate, Cyclophosphamide, Mycophenolate, Cladribine, Rituximab).
  • Contraindications to treatment with Natalizumab.
  • History of Progressive Multifocal Leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.
  • Immunocompromised at the time of enrollment. Known active malignancies.
  • Inability to comply with study requirements.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Treatment and study plan

Natalizumab

Drug

As described in the treatment arm.

Other names: Tysabri, BG00002

Primary outcomes

  1. Overall Disease-Free Status at Month 12

    Time frame: Month 12

  2. Clinical Disease-Free Status at Month 12 in Comparison to the Previous Year

    Time frame: Month 12

  3. Annualized Relapse Rate at Month 12 in Comparison to the Previous Year

    Time frame: Month 12

Secondary outcomes

  1. Overall Disease-Free Status at Months 24, 36 and 48

    Time frame: Months 24, 36 and 48

  2. Clinical Disease-free Status Every 6 Months

    Time frame: Every 6 months (Up to 48 months)

  3. Annualized Relapse Rate (ARR)

    Time frame: Months 12, 24, 36 and 48

  4. Change From Baseline in Sustained Expanded Disability Status Scale (EDSS) Score (24-week Sustained)

    Time frame: Months 12, 24, 36 and 48

    The EDSS is used to quantify disability due to symptoms of MS and to track changes in disability status over time. Scores range from 0 (normal neurological exam) to 10 (death due to multiple sclerosis).

  5. MRI measures: T2, T1, T1 with Gadolinium (Gd)

    Time frame: Months 12, 24, 36 and 48

  6. Cognitive Impairment Using Symbol Digit Modalities Test (SDMT)

    Time frame: Months 12, 24, 36 and 48

  7. Change From Baseline in Ability to Work and Productivity as Assessed by Work Productivity and Activity Impairment (WPAI) Questionnaire

    Time frame: Months 12, 24, 36 and 48

    The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages ranging from 0-100%, with higher numbers indicating greater impairment and less productivity.

  8. Quality of life (QoL) Assessed Using Fatigue Severity Scale

    Time frame: Months 12, 24, 36 and 48

    The FSS is a self-assessment questionnaire that provides a score as a measurement of the severity of fatigue. It consists of 9 questions scored from 1 to 7. A low value (e.g., 1); indicates strong disagreement with the statement, whereas a high value (e.g., 7); indicates strong agreement. A total score of 36 or more suggests presence of fatigue.

  9. QoL assessed using Multiple Sclerosis Functional Composite (MSFC) Test

    Time frame: Months 12, 24, 36 and 48

    MSFC has 2 component- timed 25-foot walk (T25FW) and 9-hole peg test (9HPT) [dominant and nondominant hands]. The MSFC Z-score is calculated by creating Z-scores for each component of the MSFC and averaging them to create an overall composite score. MSFC Z-score = (Z25-foot-walk + Z9HPT-2)/2, where Zj refers to Z-scores of component j. A Z-score represented the number of standard deviations participant's test result was higher (Z >0) or lower (Z <0) than the average test result (Z = 0) from the reference population. Higher scores indicate better outcomes.

  10. QoL Assessed Using Beck Depression Inventory, 2nd Edition (BDI-II)

    Time frame: Months 12, 24, 36 and 48

    BDI-II Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represents a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe). Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression.

  11. QoL Assessed Using Multiple Sclerosis Impact Scale (MSIS-29)

    Time frame: Months 12, 24, 36 and 48

    MSIS-29 is a brief self-administered instrument measuring physical (20 items) and psychological (9 items) impact of Multiple Sclerosis (MS). Each of the 29 items on MSIS-29 tool is a question that ask for participants views about the impact of MS on their day to day lives. Each item is scored on 1 to 5 (1=Not at all; 5=Extremely).

Sponsors and collaborators

Lead sponsor

Biogen

Industry

Registry information

Official study title

Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients - TYPIFI (Tysabri Patient Initiation After Failure of the Initial DMT)

Acronym: TYPIFI

Important dates

Study start
2013
Primary completion
2023
Study completion
2023
First posted
Apr 5, 2021
Registry last updated
Feb 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.